Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256639 | 0.89 | DRD2 (0.46) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL13997815 | 0.86 | ADRB2 (0.49) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL27770720 | 0.85 | SYK (0.44) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL12321493 | 0.84 | SYK (0.46) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL23011458 | 0.84 | SYK (0.44) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL256636 | 0.84 | SYK (0.44) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL4582959 | 0.83 | DRD2 (0.49) | ADRB2ADRB1SYKMALT1LMNA | |
| SCHEMBL12438458 | 0.82 | CA12 (0.55) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL29848484 | 0.82 | PTGFR (0.46) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL21609310 | 0.82 | PTGFR (0.46) | ADRB2ADRB1CYP2D6NFKB1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
| CN-103370309-A | Substituted N-phenethyltriazoloneacetamides and use thereof | BAYER IP GMBH | 2013-10-23 | — | — | CN | disclosed |
| US-8299075-B2 | Substituted thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | disclosed |
| US-20110294787-A1 | SUBSTITUTED THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2011-12-01 | — | — | US | disclosed |
| US-8012962-B2 | Substituted thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2011-09-06 | — | — | US | disclosed |
| US-7812023-B2 | Methods of using substituted morpholine derivatives | H. LUNDBECK A/S (DK) | 2010-10-12 | — | — | US | disclosed |
| US-20100063033-A1 | Methods of using substituted morpholine derivatives | H. LUNDBECK A/S (DK) | 2010-03-11 | — | — | US | disclosed |
| US-20100063036-A1 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2010-03-11 | — | — | US | disclosed |
| EP-1947093-B9 | Substituted morpholine and thiomorpholine derivatives | LUNDBECK & CO AS H (DK) | 2010-03-03 | — | — | EP | disclosed |
| EP-1947093-B1 | Substituted morpholine and thiomorpholine derivatives | LUNDBECK & CO AS H (DK) | 2009-09-23 | — | — | EP | disclosed |
| US-20090143369-A1 | METHODS OF USING SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090137571-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| US-7501414-B2 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2009-03-10 | — | — | US | disclosed |
| EP-1727809-B8 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2008-10-29 | — | — | EP | disclosed |
| EP-1947093-A1 | Substituted morpholine and thiomorpholine derivatives | H. Lundbeck A/S (DK) | 2008-07-23 | — | — | EP | disclosed |
| EP-1727809-B1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2008-06-11 | — | — | EP | disclosed |
| EP-1727809-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H.Lundbeck A/S (DK) | 2006-12-06 | — | — | EP | disclosed |
| US-20060167248-A1 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| WO-2005087754-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | ADRB2 871/4885ADRB1 1289/4885CYP2D6 1640/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | ADRB2 871/4885ADRB1 1289/4885CYP2D6 1640/4885 |
| US-20060167248-A1 | Substituted morpholine and thiomorpholine derivatives | OPRM1, OPRK1, OPRD1 | ADRB2 21/4885ADRB1 32/4885CYP2D6 58/4885 |
| US-20100063033-A1 | Methods of using substituted morpholine derivatives | OPRM1, TPMT, SIGMAR1 | ADRB2 23/4885ADRB1 38/4885CYP2D6 37/4885 |
| US-20090137571-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | OPRM1, OPRK1, OPRD1 | ADRB2 25/4885ADRB1 41/4885CYP2D6 62/4885 |
| US-20090143369-A1 | METHODS OF USING SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | OPRM1, TPMT, OPRK1 | ADRB2 36/4885ADRB1 45/4885CYP2D6 48/4885 |
| US-20110294787-A1 | SUBSTITUTED THIOMORPHOLINE DERIVATIVES | OPRM1, OPRK1, OPRL1 | ADRB2 18/4885ADRB1 26/4885CYP2D6 56/4885 |
| US-20100063036-A1 | Substituted morpholine and thiomorpholine derivatives | OPRM1, OPRK1, OPRD1 | ADRB2 21/4885ADRB1 32/4885CYP2D6 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.